QQQ   292.96 (+0.93%)
AAPL   143.54 (+0.38%)
MSFT   245.97 (+1.34%)
META   147.99 (+0.63%)
GOOGL   97.70 (+0.78%)
AMZN   103.01 (+2.45%)
TSLA   172.95 (+3.77%)
NVDA   195.14 (+1.84%)
NIO   12.21 (+1.58%)
BABA   110.94 (-0.23%)
AMD   74.30 (+2.55%)
T   20.20 (+0.20%)
MU   60.01 (-2.75%)
F   13.33 (+3.41%)
CGC   2.93 (+3.17%)
GE   80.57 (-0.32%)
DIS   108.21 (+0.58%)
AMC   5.13 (+2.40%)
PFE   43.56 (+0.02%)
PYPL   80.85 (+1.52%)
NFLX   353.95 (+0.24%)
QQQ   292.96 (+0.93%)
AAPL   143.54 (+0.38%)
MSFT   245.97 (+1.34%)
META   147.99 (+0.63%)
GOOGL   97.70 (+0.78%)
AMZN   103.01 (+2.45%)
TSLA   172.95 (+3.77%)
NVDA   195.14 (+1.84%)
NIO   12.21 (+1.58%)
BABA   110.94 (-0.23%)
AMD   74.30 (+2.55%)
T   20.20 (+0.20%)
MU   60.01 (-2.75%)
F   13.33 (+3.41%)
CGC   2.93 (+3.17%)
GE   80.57 (-0.32%)
DIS   108.21 (+0.58%)
AMC   5.13 (+2.40%)
PFE   43.56 (+0.02%)
PYPL   80.85 (+1.52%)
NFLX   353.95 (+0.24%)
QQQ   292.96 (+0.93%)
AAPL   143.54 (+0.38%)
MSFT   245.97 (+1.34%)
META   147.99 (+0.63%)
GOOGL   97.70 (+0.78%)
AMZN   103.01 (+2.45%)
TSLA   172.95 (+3.77%)
NVDA   195.14 (+1.84%)
NIO   12.21 (+1.58%)
BABA   110.94 (-0.23%)
AMD   74.30 (+2.55%)
T   20.20 (+0.20%)
MU   60.01 (-2.75%)
F   13.33 (+3.41%)
CGC   2.93 (+3.17%)
GE   80.57 (-0.32%)
DIS   108.21 (+0.58%)
AMC   5.13 (+2.40%)
PFE   43.56 (+0.02%)
PYPL   80.85 (+1.52%)
NFLX   353.95 (+0.24%)
QQQ   292.96 (+0.93%)
AAPL   143.54 (+0.38%)
MSFT   245.97 (+1.34%)
META   147.99 (+0.63%)
GOOGL   97.70 (+0.78%)
AMZN   103.01 (+2.45%)
TSLA   172.95 (+3.77%)
NVDA   195.14 (+1.84%)
NIO   12.21 (+1.58%)
BABA   110.94 (-0.23%)
AMD   74.30 (+2.55%)
T   20.20 (+0.20%)
MU   60.01 (-2.75%)
F   13.33 (+3.41%)
CGC   2.93 (+3.17%)
GE   80.57 (-0.32%)
DIS   108.21 (+0.58%)
AMC   5.13 (+2.40%)
PFE   43.56 (+0.02%)
PYPL   80.85 (+1.52%)
NFLX   353.95 (+0.24%)
NASDAQ:RARE

Ultragenyx Pharmaceutical - RARE Stock Forecast, Price & News

$44.59
+1.61 (+3.75%)
(As of 01/31/2023 11:39 AM ET)
Add
Compare
Today's Range
$43.23
$44.97
50-Day Range
$34.59
$47.44
52-Week Range
$33.36
$85.53
Volume
150,549 shs
Average Volume
665,562 shs
Market Capitalization
$3.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$92.00

Ultragenyx Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
111.0% Upside
$92.00 Price Target
Short Interest
Bearish
5.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
0.68mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$89,283 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.84) to ($7.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

211th out of 1,055 stocks

Pharmaceutical Preparations Industry

100th out of 518 stocks


RARE stock logo

About Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010, and is headquartered in Novato, CA.

Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Stock News Headlines

Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
Ultragenyx Announces Departure of Chief Financial Officer
Ultragenyx Pharma Q3 Loss Widens
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx to Participate at Citi BioPharma Conference
See More Headlines
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Company Calendar

Last Earnings
11/02/2022
Today
1/31/2023
Next Earnings (Estimated)
2/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RARE
Employees
1,119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$92.00
High Stock Price Forecast
$142.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+106.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-454,020,000.00
Net Margins
-197.47%
Pretax Margin
-195.38%

Debt

Sales & Book Value

Annual Sales
$351.41 million
Book Value
$13.53 per share

Miscellaneous

Free Float
65,409,000
Market Cap
$3.13 billion
Optionable
Optionable
Beta
1.01

Key Executives

  • Emil D. KakkisEmil D. Kakkis
    President, Chief Executive Officer & Director
  • Dennis Karl HuangDennis Karl Huang
    Chief Technical Operations Officer & Senior VP
  • Samuel C. Wadsworth
    Chief Scientific Office
  • Camille L. BedrosianCamille L. Bedrosian
    Chief Medical Officer & Executive Vice President
  • Thomas Richard KassbergThomas Richard Kassberg
    Chief Business Officer & Executive Vice President













RARE Stock - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RARE shares.
View RARE analyst ratings
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price forecast for 2023?

12 analysts have issued twelve-month price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price forecasts range from $50.00 to $142.00. On average, they anticipate the company's share price to reach $92.00 in the next year. This suggests a possible upside of 106.3% from the stock's current price.
View analysts price targets for RARE
or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2023?

Ultragenyx Pharmaceutical's stock was trading at $46.33 on January 1st, 2023. Since then, RARE shares have decreased by 3.8% and is now trading at $44.59.
View the best growth stocks for 2023 here
.

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our RARE earnings forecast
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its earnings results on Wednesday, November, 2nd. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing analysts' consensus estimates of ($2.29) by $0.14. The biopharmaceutical company earned $90.70 million during the quarter, compared to the consensus estimate of $98.76 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 84.14% and a negative net margin of 197.47%.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.23%), Peregrine Capital Management LLC (0.21%), Pinnacle Associates Ltd. (0.18%), New York State Common Retirement Fund (0.10%), Hennion & Walsh Asset Management Inc. (0.02%) and Natixis Advisors L.P. (0.01%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $44.59.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $3.13 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454,020,000.00 in net income (profit) each year or ($9.74) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

The company employs 1,119 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.

This page (NASDAQ:RARE) was last updated on 1/31/2023 by MarketBeat.com Staff